cefadroxil Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 526 50370-12-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefadroxil
  • cefadrox
  • cephadroxil
  • cefadroxil hemihydrate
Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.
  • Molecular weight: 363.39
  • Formula: C16H17N3O5S
  • CLOGP: -2.51
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 4
  • TPSA: 132.96
  • ALOGS: -2.96
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 14.20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 93 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 78.62 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 95 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.23 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.39 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 17, 1978 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Type IV hypersensitivity reaction 262.18 23.70 48 1356 2492 46682166
Rash maculo-papular 127.80 23.70 43 1361 27831 46656827
Oedema 64.43 23.70 34 1370 67037 46617621
Drug hypersensitivity 53.98 23.70 50 1354 243775 46440883
Veillonella infection 28.44 23.70 4 1400 36 46684622
Drug reaction with eosinophilia and systemic symptoms 28.35 23.70 15 1389 29533 46655125
Neisseria infection 27.63 23.70 4 1400 45 46684613
Cellulitis 24.94 23.70 19 1385 70269 46614389
Stomatococcal infection 24.70 23.70 4 1400 98 46684560
Immunodeficiency common variable 24.09 23.70 4 1400 115 46684543

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC J01DB05 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
First-generation cephalosporins
CHEBI has role CHEBI:36047 antibacterial drugs
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Infection of skin AND/OR subcutaneous tissue indication 19824006
Streptococcal tonsillitis indication 41582007
Klebsiella cystitis indication 60867007
Urinary tract infectious disease indication 68566005
Tonsillitis indication 90176007 DOID:10456
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Streptococcus pyogenes infection indication 302809008
Infection due to Staphylococcus aureus indication 406602003
Prevention of Bacterial Endocarditis off-label use
Impaired renal function disorder contraindication 197663003
Pseudomembranous enterocolitis contraindication 397683000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.77 acidic
pKa2 9.72 acidic
pKa3 13.53 acidic
pKa4 7.63 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Solute carrier family 15 member 1 Transporter Ki 2.14 WOMBAT-PK
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL

External reference:

IDSource
4018151 VUID
N0000146488 NUI
D00257 KEGG_DRUG
66592-87-8 SECONDARY_CAS_RN
4018151 VANDF
C0007538 UMLSCUI
CHEBI:53667 CHEBI
CHEMBL1644 ChEMBL_ID
DB01140 DRUGBANK_ID
D002434 MESH_DESCRIPTOR_UI
47965 PUBCHEM_CID
4831 IUPHAR_LIGAND_ID
280111G160 UNII
1297878 RXNORM
d00080 MMSL
004959 NDDF
13414000 SNOMEDCT_US
372651006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 0093-3196 CAPSULE 500 mg ORAL ANDA 22 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 0093-4059 TABLET 1000 mg ORAL ANDA 23 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 0143-9766 POWDER, FOR SUSPENSION 500 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 0143-9767 POWDER, FOR SUSPENSION 250 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 0143-9947 CAPSULE 500 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 0143-9948 TABLET, FILM COATED 1 g ORAL ANDA 23 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 10544-135 CAPSULE 500 mg ORAL ANDA 19 sections
CEFADROXIL Human Prescription Drug Label 1 16590-043 CAPSULE 500 mg ORAL ANDA 23 sections
Cefadroxil Human Prescription Drug Label 1 16714-388 CAPSULE 500 mg ORAL ANDA 21 sections
Cefadroxil Human Prescription Drug Label 1 16714-389 POWDER, FOR SUSPENSION 250 mg ORAL ANDA 21 sections
Cefadroxil Human Prescription Drug Label 1 16714-390 POWDER, FOR SUSPENSION 500 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 21695-427 CAPSULE 500 mg ORAL ANDA 22 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 33261-018 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 42254-146 CAPSULE 500 mg ORAL ANDA 19 sections
CEFADROXIL Human Prescription Drug Label 1 42549-504 CAPSULE 500 mg ORAL ANDA 23 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 43063-553 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 43063-595 CAPSULE 500 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 45865-503 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil Human Prescription Drug Label 1 50090-1915 CAPSULE 500 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 52959-428 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 53002-2290 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 54868-3742 CAPSULE 500 mg ORAL ANDA 13 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 54868-5693 POWDER, FOR SUSPENSION 250 mg ORAL ANDA 14 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 54868-5694 POWDER, FOR SUSPENSION 500 mg ORAL ANDA 14 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 55289-589 CAPSULE 500 mg ORAL ANDA 21 sections
Cefadroxil Human Prescription Drug Label 1 57237-096 CAPSULE 500 mg ORAL ANDA 21 sections
Cefadroxil Human Prescription Drug Label 1 57237-097 POWDER, FOR SUSPENSION 250 mg ORAL ANDA 21 sections
Cefadroxil Human Prescription Drug Label 1 57237-098 POWDER, FOR SUSPENSION 500 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 57297-180 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 63187-883 CAPSULE 500 mg ORAL ANDA 19 sections